Related Experiment Video

Updated: May 26, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes

Sara Tehrani1, Aleksandra Antovic, Fariborz Mobarrez

  • 1Division of Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. sara.tehrani@ds.se

Diabetes Care
|December 8, 2011
PubMed

Insights

High-dose aspirin (320 mg) improved fibrin network permeability in type 1 diabetes patients, unlike low-dose aspirin. This suggests higher aspirin doses may be needed to effectively manage cardiovascular disease risk in this population.

Area of Science:

  • Cardiovascular Disease Research
  • Diabetes Mellitus Therapeutics
  • Hematology and Thrombosis

Background:

  • Type 1 diabetes is associated with a less permeable fibrin network, increasing cardiovascular disease (CVD) risk.
  • Standard low-dose aspirin treatment for CVD may be less effective in diabetic patients.
  • Aspirin's impact on fibrin network permeability and its interaction with glycemic control in type 1 diabetes requires investigation.

Purpose of the Study:

  • To investigate the effects of low- and high-dose aspirin on fibrin network formation in type 1 diabetes patients.
  • To explore the interaction between aspirin dosage, fibrin network permeability, and glycemic control in type 1 diabetes.

Main Methods:

  • Forty-eight type 1 diabetes patients (24 good, 24 poor glycemic control) were randomized to 75 mg or 320 mg aspirin daily for 4 weeks in a crossover design.
  • A 4-week washout period was implemented between treatments.
  • Plasma fibrin network permeability was assessed using the permeability coefficient (K(s)).

Main Results:

  • 75 mg aspirin did not affect fibrin network permeability (K(s)).
  • 320 mg aspirin significantly increased K(s) (P = 0.004) compared to 75 mg (P = 0.009).
  • The increase in K(s) with high-dose aspirin was significant in patients with poor glycemic control (P = 0.02) and trended in those with good control (P = 0.06).

Conclusions:

  • A high aspirin dose (320 mg) is necessary to alter fibrin network permeability in type 1 diabetes.
  • Low-dose aspirin's lack of effect on fibrin permeability may explain treatment failure in diabetes.
  • Findings highlight the importance of aspirin dosage in managing CVD risk in type 1 diabetes.
Abstract

More Related Videos

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy06:27

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...